basic+care — Class II drug recall D-0331-2022
Terminated recall by Perrigo Company PLC, reported 2022-01-12, distributed nationwide. Failed Impurities/Degradation Specifications; Out of specification result obtained for impurity A during stabi
| Recall number | D-0331-2022 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Perrigo Company PLC, Allegan, MI, United States |
| Recall initiated | 2021-07-27 |
| Classified | 2022-01-05 |
| Reported by FDA | 2022-01-12 |
| Terminated | 2022-11-08 |
| Distributed | Nationwide (US) |
| Quantity | 28,320 containers |
| Reason classes | specification failure |
| UPC / GTIN / UDI-DI | 00370030114702 |
| NDC | 00113-7571-47 |
| Lot numbers | 0GR0528, 0KR0473, 0LR0369 |
| Expiration dates | 2022-03-31, 2022-04-30, 2022-06-30 |
Product
basic+care, allergy Fexofenadine Hydrochloride Tablets, 180 mg/Antihistamine, 24 HR, 150 count bottle, Made in the Czech Republic, Distributed by: Perrigo Allergan, MI 49010, NDC 0113-7571-47 UPC 3 70030 11470 2
Reason for recall
Failed Impurities/Degradation Specifications; Out of specification result obtained for impurity A during stability testing.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0331-2022. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.